NCT00790842 2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT01355705 2018-09-18
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Stanford University
Phase 1/2 Completed
NCT00833833 2016-04-27
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
Phase 1/2 Completed
NCT00691704 2014-08-19
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Duke University
Phase 2 Completed